Panretin

Alitretinoin (9-cis-retinoic acid) is an FDA-approved topical therapy for the treatment of Kaposi sarcoma. Alitretinoin is a… (More)

Rexinoids binding to both the retinoic acid receptor (RAR) and retinoid X receptor (RXR) families of rexinoid receptors have… (More)

OBJECTIVE To assess the efficacy, safety and tolerance of oral 9-cis-retinoic acid in HIV-infected patients with Kaposi's sarcoma… (More)

This review focuses on the use of alitretinoin (Panretin) gel 0.1% therapy as a new topical treatment of cutaneous lesions in… (More)

OBJECTIVE To evaluate the efficacy and safety of topical alitretinoin gel (9-cis-retinoic acid [LGD1057], Panretin gel; Ligand… (More)

Kaposi's sarcoma (KS) is the most common malignancy associated with the acquired immunodeficiency syndrome (AIDS). Recent years… (More)

BACKGROUND Kaposi's sarcoma (KS) is the most frequent malignancy in patients with HIV. Given the promise that retinoids show in… (More)

Ligand Pharmaceuticals has received FDA approval for Panretin Gel (alitretinoin) for topical treatment of Kaposi's sarcoma. The… (More)

 

Retinoids are compounds that bind to and activate one or more retinoid receptors to elicit various physiological responses. There… (More)